surmount-1 tirzepatide weight loss percent 72 weeks for Obesity Treatment and Diabetes Prevention Tirzepatide (ZEPBOUND) Approved for Chronic

LONDON The U.K

Thats important because other similar injectable weight loss medications, like Wegovy (semaglutide), only mimic GLP-1

Although the intraperitoneal administration of exendin 939 did not cause adverse hyperthermia effects, a critical aspect of developing TRPV1 antagonists is minimizing interference with TRPV1 activation by protons and hence identifying mode-selective antagonists 32

Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data